- Markets
- Healthcare
- WANBURY
WANBURY
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Indian pharma firm Wanbury gains on product launch plans
** Wanbury's shares WANB.NS rise 9%, set for fifth straight session of gains
** Pharma co to launch two new products for formulation, including iron tablets and Ketamine
** Over 255,000 shares traded, 1.6x WANB's 30-day avg
** Stock has surged ~41% in March vs a ~10% rise in Nifty pharma index .NIPHARM
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Wanbury's shares WANB.NS rise 9%, set for fifth straight session of gains
** Pharma co to launch two new products for formulation, including iron tablets and Ketamine
** Over 255,000 shares traded, 1.6x WANB's 30-day avg
** Stock has surged ~41% in March vs a ~10% rise in Nifty pharma index .NIPHARM
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
Wanbury To Issue NCDs Up To 2 Billion Rupees
Feb 12 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - TO ISSUE NCDS UP TO 2 BILLION RUPEES
Source text: ID:nBSE6vRkTp
Further company coverage: WANB.NS
(([email protected];))
Feb 12 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD - TO ISSUE NCDS UP TO 2 BILLION RUPEES
Source text: ID:nBSE6vRkTp
Further company coverage: WANB.NS
(([email protected];))
Wanbury Completes ANVISA Audit At Tanuku Plant
Jan 3 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY - COMPLETES ANVISA AUDIT AT TANUKU PLANT
WANBURY - FULL-FLEDGED MANUFACTURING OPERATIONS STARTED AT TANUKU PLANT
Source text: ID:nBSEbxM8RV
Further company coverage: WANB.NS
(([email protected];))
Jan 3 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY - COMPLETES ANVISA AUDIT AT TANUKU PLANT
WANBURY - FULL-FLEDGED MANUFACTURING OPERATIONS STARTED AT TANUKU PLANT
Source text: ID:nBSEbxM8RV
Further company coverage: WANB.NS
(([email protected];))
Wanbury Says Tanuku Plant Completes Anvisa Inspection
Dec 20 (Reuters) - Wanbury Ltd WANB.NS:
TANUKU PLANT COMPLETES ANVISA INSPECTION
INSPECTION COMPLETED WITH ZERO OBSERVATIONS FOR 5 APIS
Source text: ID:nBSE1W24Ym
Further company coverage: WANB.NS
(([email protected];;))
Dec 20 (Reuters) - Wanbury Ltd WANB.NS:
TANUKU PLANT COMPLETES ANVISA INSPECTION
INSPECTION COMPLETED WITH ZERO OBSERVATIONS FOR 5 APIS
Source text: ID:nBSE1W24Ym
Further company coverage: WANB.NS
(([email protected];;))
India's Wanbury rises after Maharashtra facility gets U.S. FDA nod
** Shares of Wanbury WANB.NS rise 4.45% to 218.49 rupees
** Pharma co gets establishment inspection report (EIR) from U.S. FDA for its Maharashtra facility
** Inspection classified as "no action indicated" with "zero Form-483 observations"
** Zero Form-483 observations indicate the facility is in acceptable state of compliance with current good manufacturing practices
** Stock up about 17% this week, on course for best weekly performance since September 2023 - NSE data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Shares of Wanbury WANB.NS rise 4.45% to 218.49 rupees
** Pharma co gets establishment inspection report (EIR) from U.S. FDA for its Maharashtra facility
** Inspection classified as "no action indicated" with "zero Form-483 observations"
** Zero Form-483 observations indicate the facility is in acceptable state of compliance with current good manufacturing practices
** Stock up about 17% this week, on course for best weekly performance since September 2023 - NSE data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
India's Wanbury rises after USFDA inspection shows zero observations
** Shares of Wanbury Ltd WANB.NS rise as much as 5%, before trimming gains to trade 4.2% higher
** Pharma co said United States Food and Drug Administration completed inspection at co's Patalganga site in Maharashtra with zero observations
** Stock set for best one-day rise in a month
** Stock set to rise for a fifth straight quarter, gaining nearly 4x in the last four quarters
** Trading vol is 1.5x the 30-day daily avg
** Stock up ~31% in 2024 so far, after gaining 2.5x in 2023
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected] ;))
** Shares of Wanbury Ltd WANB.NS rise as much as 5%, before trimming gains to trade 4.2% higher
** Pharma co said United States Food and Drug Administration completed inspection at co's Patalganga site in Maharashtra with zero observations
** Stock set for best one-day rise in a month
** Stock set to rise for a fifth straight quarter, gaining nearly 4x in the last four quarters
** Trading vol is 1.5x the 30-day daily avg
** Stock up ~31% in 2024 so far, after gaining 2.5x in 2023
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected] ;))
Wanbury March-Qtr Consol PAT Rises
May 16 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD MARCH-QUARTER CONSOL PAT 336.3 MILLION RUPEES VERSUS 10.2 MILLION RUPEES
WANBURY LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.39 BILLION RUPEES VERSUS 1.33 BILLION RUPEES
Source text for Eikon: ID:nNSEzHxMk
Further company coverage: WANB.NS
(([email protected];;))
May 16 (Reuters) - Wanbury Ltd WANB.NS:
WANBURY LTD MARCH-QUARTER CONSOL PAT 336.3 MILLION RUPEES VERSUS 10.2 MILLION RUPEES
WANBURY LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.39 BILLION RUPEES VERSUS 1.33 BILLION RUPEES
Source text for Eikon: ID:nNSEzHxMk
Further company coverage: WANB.NS
(([email protected];;))
India's Wanbury Sept-Quarter Consol PAT At 73.6 Million Rupees
Oct 20 (Reuters) - Wanbury Ltd WANB.NS:
INDIA'S WANBURY LTD SEPT-QUARTER CONSOL PAT 73.6 MILLION RUPEES VERSUS LOSS 8.9 MILLION RUPEES YEAR AGO
WANBURY LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.44 BILLION RUPEES VERSUS 1.24 BILLION RUPEES YEAR AGO
WANBURY LTD - APPROVED ISSUE OF CONVERTIBLE WARRANTS WORTH UPTO 240 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: WANB.NS
(([email protected];))
Oct 20 (Reuters) - Wanbury Ltd WANB.NS:
INDIA'S WANBURY LTD SEPT-QUARTER CONSOL PAT 73.6 MILLION RUPEES VERSUS LOSS 8.9 MILLION RUPEES YEAR AGO
WANBURY LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.44 BILLION RUPEES VERSUS 1.24 BILLION RUPEES YEAR AGO
WANBURY LTD - APPROVED ISSUE OF CONVERTIBLE WARRANTS WORTH UPTO 240 MILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: WANB.NS
(([email protected];))
Wanbury To Consider Raising Of Funds
Oct 17 (Reuters) - Wanbury Ltd WANB.NS:
TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSEbV0Sf3
Further company coverage: WANB.NS
(([email protected];))
Oct 17 (Reuters) - Wanbury Ltd WANB.NS:
TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSEbV0Sf3
Further company coverage: WANB.NS
(([email protected];))
India's Wanbury Reports Profit For June-Qtr
Aug 11 (Reuters) - Wanbury Ltd WANB.NS:
INDIA'S WANBURY JUNE-QUARTER CONSOL PAT 46.9 MILLION RUPEES VERSUS LOSS 72.4 MILLION RUPEES
WANBURY JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.46 BILLION RUPEES VERSUS 1.17 BILLION RUPEES
Source text for Eikon: ID:nBSE9qKvsj
Further company coverage: WANB.NS
(([email protected];;))
Aug 11 (Reuters) - Wanbury Ltd WANB.NS:
INDIA'S WANBURY JUNE-QUARTER CONSOL PAT 46.9 MILLION RUPEES VERSUS LOSS 72.4 MILLION RUPEES
WANBURY JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.46 BILLION RUPEES VERSUS 1.17 BILLION RUPEES
Source text for Eikon: ID:nBSE9qKvsj
Further company coverage: WANB.NS
(([email protected];;))
Wanbury To Consider Issue Of Nonconvertible Debentures On Private Placement Basis
July 6 (Reuters) - Wanbury Ltd WANB.NS:
TO CONSIDER ISSUE OF NONCONVERTIBLE DEBENTURES ON PRIVATE PLACEMENT BASIS
Source text for Eikon: ID:nBSE3Kv3vR
Further company coverage: WANB.NS
(([email protected];))
July 6 (Reuters) - Wanbury Ltd WANB.NS:
TO CONSIDER ISSUE OF NONCONVERTIBLE DEBENTURES ON PRIVATE PLACEMENT BASIS
Source text for Eikon: ID:nBSE3Kv3vR
Further company coverage: WANB.NS
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Wanbury do?
Wanbury Limited is a prominent Indian pharmaceutical company ranked among the top 50 in the country. Specializing in API sales globally and domestic formulations, Wanbury has a significant presence in the industry.
Who are the competitors of Wanbury?
Wanbury major competitors are Kwality Pharma, Anuh Pharma, Shivalik Rasayan, Sakar Healthcare, Bharat Parenterals, Prevest Denpro, Lincoln Pharma. Market Cap of Wanbury is ₹868 Crs. While the median market cap of its peers are ₹849 Crs.
Is Wanbury financially stable compared to its competitors?
Wanbury seems to be less financially stable compared to its competitors. Altman Z score of Wanbury is 3.68 and is ranked 6 out of its 8 competitors.
Does Wanbury pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Wanbury latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Wanbury allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable
How strong is Wanbury balance sheet?
Balance sheet of Wanbury is strong. But short term working capital might become an issue for this company.
Is the profitablity of Wanbury improving?
The profit is oscillating. The profit of Wanbury is ₹43.91 Crs for TTM, ₹55.96 Crs for Mar 2024 and -₹10.4 Crs for Mar 2023.
Is the debt of Wanbury increasing or decreasing?
Yes, The debt of Wanbury is increasing. Latest debt of Wanbury is ₹164 Crs as of Sep-24. This is greater than Mar-24 when it was ₹98.28 Crs.
Is Wanbury stock expensive?
Yes, Wanbury is expensive. Latest PE of Wanbury is 19.77, while 3 year average PE is 12.98. Also latest EV/EBITDA of Wanbury is 16.35 while 3yr average is 13.05.
Has the share price of Wanbury grown faster than its competition?
Wanbury has given better returns compared to its competitors. Wanbury has grown at ~47.55% over the last 3yrs while peers have grown at a median rate of 18.8%
Is the promoter bullish about Wanbury?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Wanbury is 39.76% and last quarter promoter holding is 39.76%.
Are mutual funds buying/selling Wanbury?
There is Insufficient data to gauge this.